229 related articles for article (PubMed ID: 26353782)
21. The regulatory and predictive functions of miR-17 and miR-92 families on cisplatin resistance of non-small cell lung cancer.
Zhao J; Fu W; Liao H; Dai L; Jiang Z; Pan Y; Huang H; Mo Y; Li S; Yang G; Yin J
BMC Cancer; 2015 Oct; 15():731. PubMed ID: 26482648
[TBL] [Abstract][Full Text] [Related]
22. Lung cancer-derived Dickkopf1 is associated with bone metastasis and the mechanism involves the inhibition of osteoblast differentiation.
Chu T; Teng J; Jiang L; Zhong H; Han B
Biochem Biophys Res Commun; 2014 Jan; 443(3):962-8. PubMed ID: 24361889
[TBL] [Abstract][Full Text] [Related]
23. SKA1 regulates the metastasis and cisplatin resistance of non-small cell lung cancer.
Shen L; Yang M; Lin Q; Zhang Z; Miao C; Zhu B
Oncol Rep; 2016 May; 35(5):2561-8. PubMed ID: 26985856
[TBL] [Abstract][Full Text] [Related]
24. Protective effects of ADAM8 against cisplatin-mediated apoptosis in non-small-cell lung cancer.
Zhang W; Wan M; Ma L; Liu X; He J
Cell Biol Int; 2013 Jan; 37(1):47-53. PubMed ID: 23319321
[TBL] [Abstract][Full Text] [Related]
25. FATS expression is associated with cisplatin sensitivity in non small cell lung cancer.
Tian Y; Zhang J; Yan S; Qiu L; Li Z
Lung Cancer; 2012 Jun; 76(3):416-22. PubMed ID: 22137560
[TBL] [Abstract][Full Text] [Related]
26. The Wnt pathway regulator DKK1 is preferentially expressed in hormone-resistant breast tumours and in some common cancer types.
Forget MA; Turcotte S; Beauseigle D; Godin-Ethier J; Pelletier S; Martin J; Tanguay S; Lapointe R
Br J Cancer; 2007 Feb; 96(4):646-53. PubMed ID: 17245340
[TBL] [Abstract][Full Text] [Related]
27. Improved apoptotic cell death in drug-resistant non-small-cell lung cancer cells by tumor necrosis factor-related apoptosis-inducing ligand-based treatment.
Gatti L; Cossa G; Tinelli S; Carenini N; Arrighetti N; Pennati M; Cominetti D; De Cesare M; Zunino F; Zaffaroni N; Perego P
J Pharmacol Exp Ther; 2014 Mar; 348(3):360-71. PubMed ID: 24345465
[TBL] [Abstract][Full Text] [Related]
28. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
[TBL] [Abstract][Full Text] [Related]
29. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
Olaussen KA; Adam J; Vanhecke E; Vielh P; Pirker R; Friboulet L; Popper H; Robin A; Commo F; Thomale J; Kayitalire L; Filipits M; Le Chevalier T; André F; Brambilla E; Soria JC
Lung Cancer; 2013 May; 80(2):216-22. PubMed ID: 23410825
[TBL] [Abstract][Full Text] [Related]
30. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
[TBL] [Abstract][Full Text] [Related]
31. Wilms' tumor 1 enhances Cisplatin-resistance of advanced NSCLC.
Wu C; Wang Y; Xia Y; He S; Wang Z; Chen Y; Wu C; Shu Y; Jiang J
FEBS Lett; 2014 Dec; 588(24):4566-72. PubMed ID: 25447528
[TBL] [Abstract][Full Text] [Related]
32. Galectin-1 promotes lung cancer progression and chemoresistance by upregulating p38 MAPK, ERK, and cyclooxygenase-2.
Chung LY; Tang SJ; Sun GH; Chou TY; Yeh TS; Yu SL; Sun KH
Clin Cancer Res; 2012 Aug; 18(15):4037-47. PubMed ID: 22696230
[TBL] [Abstract][Full Text] [Related]
33. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
[TBL] [Abstract][Full Text] [Related]
34. Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer.
Oliver TG; Mercer KL; Sayles LC; Burke JR; Mendus D; Lovejoy KS; Cheng MH; Subramanian A; Mu D; Powers S; Crowley D; Bronson RT; Whittaker CA; Bhutkar A; Lippard SJ; Golub T; Thomale J; Jacks T; Sweet-Cordero EA
Genes Dev; 2010 Apr; 24(8):837-52. PubMed ID: 20395368
[TBL] [Abstract][Full Text] [Related]
35. Chemoresistance in non-small-cell lung cancer: can multidrug resistance markers predict the response of xenograft lung cancer models to chemotherapy?
Merk J; Rolff J; Dorn C; Leschber G; Fichtner I
Eur J Cardiothorac Surg; 2011 Jul; 40(1):e29-33. PubMed ID: 21420313
[TBL] [Abstract][Full Text] [Related]
36. MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer.
Chattopadhyay S; Machado-Pinilla R; Manguan-García C; Belda-Iniesta C; Moratilla C; Cejas P; Fresno-Vara JA; de Castro-Carpeño J; Casado E; Nistal M; Gonzalez-Barón M; Perona R
Oncogene; 2006 Jun; 25(23):3335-45. PubMed ID: 16462770
[TBL] [Abstract][Full Text] [Related]
37. 3'-Phosphoadenosine 5'-phosphosulfate synthase 1 (PAPSS1) knockdown sensitizes non-small cell lung cancer cells to DNA damaging agents.
Leung AW; Dragowska WH; Ricaurte D; Kwok B; Mathew V; Roosendaal J; Ahluwalia A; Warburton C; Laskin JJ; Stirling PC; Qadir MA; Bally MB
Oncotarget; 2015 Jul; 6(19):17161-77. PubMed ID: 26220590
[TBL] [Abstract][Full Text] [Related]
38. Combined Use of Gene Expression Modeling and siRNA Screening Identifies Genes and Pathways Which Enhance the Activity of Cisplatin When Added at No Effect Levels to Non-Small Cell Lung Cancer Cells In Vitro.
Leung AW; Hung SS; Backstrom I; Ricaurte D; Kwok B; Poon S; McKinney S; Segovia R; Rawji J; Qadir MA; Aparicio S; Stirling PC; Steidl C; Bally MB
PLoS One; 2016; 11(3):e0150675. PubMed ID: 26938915
[TBL] [Abstract][Full Text] [Related]
39. Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment.
Chin TM; Quinlan MP; Singh A; Sequist LV; Lynch TJ; Haber DA; Sharma SV; Settleman J
Clin Cancer Res; 2008 Nov; 14(21):6867-76. PubMed ID: 18980981
[TBL] [Abstract][Full Text] [Related]
40. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
